EUCTR2020-001610-38-DK进行中（未招募）1 期
Irbesartan and Oseltamivir treatment of COVID-19 infection. - Covid-19 protection trial
Slagelse Sygehus0 个研究点目标入组 80 人开始时间: 2020年4月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients age 50-89 years and Covid-19 positiv and home.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •Actual treatment with ACE-inhibitor, AT-II receptor antagonist or diuretics
- •Blood pressure below 110/60
- •Allergy to Irbesartan or Oseltamivir
研究者
相似试验
进行中（未招募）
1 期
osartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unitPatients with Covid-19EUCTR2020-001766-11-FRASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE90
Unknown
2 期
Atorvastatin as Adjunctive Therapy in COVID-19COVID-19NCT04380402Mount Auburn Hospital300
终止
3 期
Evaluation of Efficacity and Safety of Oseltamivir and ZanamivirGastric InfluenzaNCT00799760Assistance Publique - Hôpitaux de Paris541
Unknown
不适用
Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Registry StudyCovid19NCT04669990Nepal Health Research Council2,000
撤回
3 期
Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19Sars-CoV2NCT04372082University Hospital, Lille